MORE than 40 per cent of fertility clinics in the US are allowing couples to choose the sex of their child, a survey conducted by the Genetics and Public Policy Center (GPPC) in Washington DC suggests. The testing method, called preimplantation genetic diagnosis (PGD), was originally designed to test for severe or deadly diseases such as Tay-Sachs. It is typically performed by removing a cell from a three-day-old embryo, which is then screened for a range of chromosomal abnormalities or specific gene mutations. Seemingly healthy embryos are implanted in the womb; others are discarded or frozen. The survey, which covered 186 out of 415 fertility clinics in the US, found that around two-thirds of PGD procedures were performed to identify embryos at risk of birth defects or being miscarried.
However, the survey also revealed that applications of PGD have broadened to include choosing the baby's sex, as well as screening for diseases that may not strike until late in life, if at all. Non-medical sex selection accounted for 9 per cent of PGD tests conducted in the US in 2005, while 28 per cent of the clinics surveyed are now offering PGD to detect a propensity for adult-onset diseases such as Alzheimer's, Huntington's, hereditary breast cancer, and many other cancers.
PGD was originally intended to overcome infertility and to ensure that all children are born with a chance of a full and flourishing life, says Eric Cohen, head of the bioethics programme at the Ethics and Public Policy Center in Washington DC. "PGD clinics are performing sex selection just to satisfy parental preferences, and embryo screening is being used for late-onset diseases that have nothing to do with childhood sickness," Cohen claims. He sees these as troubling trends.
The changes are taking place because there is little consensus on which tests are appropriate for PGD, and no federal or professional oversight of the clinics, according to Susannah Baruch, who led the GPPC study. "There are more than 1000 genetic tests currently available and there is no reason why any of these couldn't be used for PDG," she says.
In the UK, PGD is regulated by the Human Fertilisation and Embryology Authority. Its spokesman John-Paul Maytum says sex selection for nonmedical purposes is not permitted in the UK because the majority of the public are against it.
The GPPC survey, which was presented at the National Genetic Policy Summit in Washington DC last week, is the first to focus specifically on the uses of PGD in IVF clinics. It revealed that almost one-quarter of US clinics use PGD to select an embryo that would be an immunological match for a sick sibling. It also showed that PGD is not error-free: 21 per cent of clinics interviewed for the study knew of cases where children had been born with diseases that PGD was supposed to eliminate.
One reason for this is that all eight cells of the embryo may not be genetically identical, due to a condition called embryo mosaicism, making it possible that the cell taken for testing may not describe the whole embryo's genetic status. Exactly how many misdiagnoses have occurred is not known, but Baruch says the survey underscores the need for better data collection and regulation to ensure the safety and efficacy of the procedure.
Author: Bijal Trivedi, Science freelance writer, Washington DC
"This article is posted on this site to give advance access to other authorised media who may wish to report on this story, or quote extracts as part of fair dealing with this copyrighted material. Full attribution is required, and if reporting online a link to www.newscientist.com is also required. This story posted here is the EXACT text used in New Scientist magazine, therefore advance permission is required before any and every reproduction of each article in full. Please contact firstname.lastname@example.org. Please note that all material is copyright of Reed Business Information Limited and we reserve the right to take such action as we consider appropriate to protect such copyright."
THIS ARTICLE APPEARS IN NEW SCIENTIST MAGAZINE ISSUE: 30 SEPTEMBER 2006
EDITOR'S NOTE: PRIOR PERMISSION IS REQUIRED BEFORE ANY REPRODUCTION OF THIS STORY IN FULL
IF REPORTING ON THIS STORY, PLEASE MENTION NEW SCIENTIST AS THE SOURCE AND, IF REPORTING ONLINE, PLEASE CARRY A HYPERLINK TO: http://www.newscientist.com
US CONTACT – New Scientist Boston office:
Tel: +1 617 386 2190 or email email@example.com
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.